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Abstract
AIM: Targeting the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is a potential
means of overcoming chemoresistance in ovarian cancer. We investigated the capability of 18F-fluororodeoxyglucose
(18F-FDG) small-animal positron emission tomography (SA-PET) to predict the effects of a dual PI3K/mTOR inhibitor
(BEZ-235) in a cisplatin-resistant ovarian cancer model. METHODS: In a first experiment, nude rats bearing sub-
cutaneous SKOV3 tumors received BEZ-235 for 3 days given alone or after paclitaxel and were compared to controls
(either untreated or that were given the excipients of paclitaxel and BEZ-235). SA-PET was performed at baseline, on
day 3, and day 7. In a second experiment aiming at further exploring the kinetics of 18F-FDG tumor uptake during the
first 48 hours following drug cessation, untreated controls were compared to rats receiving BEZ-235, which were
imaged at baseline, on day 3, on day 4, and on day 5. SA-PET results were compared to cell proliferation assessment
(Ki-67), PI3K/mTOR downstream target expression studies (pAKT and phospho-eukaryotic translation initiation factor
4E–binding protein 1), and apoptosis evaluation (cleaved caspase-3). RESULTS: In the first experiment, BEZ-235, com-
pared to untreated controls, induced a marked decrease in 18F-FDG uptake on day 3, which was correlated to a
significant decrease in cell proliferation and to a significant PI3K/mTOR pathway inhibition. No tumor necrosis or
apoptosis occurred. Four days following treatment cessation, tumor recovery (in terms of PI3K/mTOR inhibition
and cell proliferation) occurred and was identified by 18F-FDG SA-PET. Paclitaxel plus BEZ-235 showed results similar
to BEZ-235 alone. In the second experiment, PI3K/mTOR pathways exhibited partial recovery as early as 24 hours
following treatment cessation, but both 18F-FDG SA-PET and cell proliferation remained unchanged. CONCLUSIONS:
18F-FDG SA-PET is a surrogate marker of target inhibition during treatment with BEZ-235 and predicts tumor recovery
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4 days after drug withdrawal, but not during the first 48 hours following drug cessation, when a lag between PI3K/
mTOR pathway recovery and metabolic recovery is observed. 18F-FDG SA-PET could be used for therapy monitoring
of PI3K/mTOR inhibitors, but our results also raise questions regarding the potential impact of the delay between PET
imaging and the last drug intake on the accuracy of FDG imaging.
Translational Oncology (2013) 6, 586–595
Introduction
Ovarian cancers are the leading cause of death from gynecological
malignancies worldwide and the fifth most common cause of cancer
death in women [1]. The standard treatment is aggressive surgery
followed by platinum/taxane-based chemotherapy. After initial treat-
ment, platinum-resistant cancer recurs in approximately 25% of
patients within 6 months [2], and despite an initial response rate of
about 70%, most patients relapse and develop resistance to platinum-
based chemotherapy. This chemoresistance is the main cause of
treatment failure and leads to an overall survival at 5 years of less
than 30% [3]. Although several alternate options are available for the
treatment of platinum-resistant ovarian cancer, including topotecan,
liposomal doxorubicin, weekly paclitaxel, and gemcitabine as mono-
therapy [4], phase III studies suggest a similar moderate efficacy of these
different drugs, with response rates estimated to be approximately 20%
[5,6]. Therefore, there is a need for new therapeutic strategies, including
molecularly targeted therapies, to overcome this chemoresistance.
Recent data showed the biologic rationale and clinical activity of
mammalian target of rapamycin (mTOR) inhibitors in gynecological
cancers [7]. Indeed, a recent prospective large-scale genomic analysis
has shown that the phosphoinositide 3-kinase (PI3K)/AKT pathway
is frequently deregulated in high-grade serous ovarian tumors [8].
Furthermore, simultaneous AKT and mTOR activation can be pre-
sent in up to 87% of ovarian tumors [9]. PI3K can be considered as a
major mediator of survival signals that protect ovarian cancer from
apoptosis induction [10].
BEZ-235 is a novel oral therapeutic agent that inhibits two key
proteins of the PI3K/AKT/mTOR pathway, the PI3K and mTOR
proteins, and it is currently evaluated in phase I clinical trials [11].
While no clinical trials using BEZ-235 in the setting of cis-platinum–
resistant ovarian tumors are currently registered, preclinical data
showed that BEZ-235 decreases cell proliferation in ovarian cancer
cell lines and sensitizes cisplatin-resistant cells to the cytotoxic effects
of cisplatin [12]. In preclinical studies where it was used as a single
agent, this drug seems primarily to promote tumor stasis and delay
progression rather than activate apoptotic mechanisms inducing cell
death and tumor shrinkage [10]. In in vitro and in vivo studies that
combined a PI3K inhibitor (LY294002) with paclitaxel—a drug
widely used in ovarian cancer—in ovarian cancer, an increased effi-
cacy of the chemotherapy on tumor cell growth and dissemination
compared with either agent alone was observed [13]. Therefore,
BEZ-235 given alone or in association with paclitaxel holds promise
for the treatment of cis-platinum–resistant ovarian cancer. However,
there is no biomarker capable of predicting the benefit of BEZ-235.
Indeed, it has been shown that PI3K mutations do not predict for
the sensitivity of ovarian cell carcinoma cells to PI3K/AKT/mTOR
inhibitors [14]. Positron emission tomography (PET) imaging has been
shown to be particularly useful for evaluating the efficacy of molecularly
targeted therapies given either alone or in combination with con-
ventional chemotherapies in preclinical studies [15]. In particular,
18F-fluororodeoxyglucose (18F-FDG) uptake has been shown to be an
early surrogate marker of drug efficacy during mTOR inhibition [16].
The aim of this study was to evaluate the ability of 18F-FDG PET
to predict early response to BEZ-235 given alone or associated to
paclitaxel in a rat model of subcutaneously transplanted human cisplatin-
resistant ovarian cancer. 18F-FDG PET results were correlated not only
to tumor response early after treatment but also to tumor recovery after
drug discontinuation.
Materials and Methods
Cell Line Culture
The SKOV3 cell line (American Type Cell Collection, Manassas,
VA) was cultured in 450-cm2 flasks in RPMI 1640 medium supple-
mented with 2 mM Glutamax, 25 mM Hepes, 10% fetal calf serum,
and 33 mM sodium bicarbonate (Fisher Scientific Bioblock, Illkirch,
France) at 37°C in a 95% humidified air, 5% CO2 atmosphere. All
cell culture media and components were from Gibco Life Technol-
ogies (Cergy Pontoise, France).
Animal Model
Four-week-old female nude rats (n = 28; Harlan Laboratories,
Indianapolis, IN) were injected subcutaneously with the SKOV3
human ovarian cancer cell line. Each animal received four injections:
two in the shoulders and two in the upper part of the thighs. We grafted
four tumors per animal to limit the number of animals killed and to
maximize the number of tumors imaged within a small-animal PET
(SA-PET)/computed tomography (CT) imaging session. Syringes were
prepared as follows: 10 × 106 SKOV3 cells in 0.2 ml of 50% RPMI/
Matrigel (BD Biosciences, Franklin Lakes, NJ). The SKOV3 cell line
was chosen because it is a cisplatin-resistant cell line that matches
well with the dilemma encountered in the clinical setting. To improve
the tumor take rate, animals received a single, 2-Gy dose of whole-
body irradiation 24 hours before cell implantation. Animals were kept
under pathogen-free conditions and allowed to feed freely. Treatments
began when the largest tumor measured 7 to 10 mm in diameter.
Animal experiments were approved by the regional Ethics Committee
(No. N/02-10-09/18/10-12).
Drug Preparation
Paclitaxel (Mylan Pharma, Canonsburg, PA) was diluted in a perito-
neal dialysis solution (Dianeal; Baxter, Deerfield, IL) according to
previous studies, and 10 ml of this preparation was administered intra-
peritoneally at 5mg/kg on day 0. BEZ-235 (SelleckChemicals,Houston,
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TX) was diluted with a polyethylene glycol (Sigma-Aldrich, St Louis,
MO) and N -methyl-2-pyrrolidone (Sigma-Aldrich) solution and was
administered orally at 50 mg/kg on day 1 (24 hours after paclitaxel
injection), day 2, and day 3. The control animals received a Cremophor
EL (Sigma-Alrich) and ethanol solution on day 0 and an N -methyl-2-
pyrrolidone/polyethylene glycol solution from day 1 to day 3, which
are the excipients of paclitaxel and BEZ-235, respectively [11].
Study Design
In a first experiment, two cohorts of rats were used (Table 1). The
first consisted of 14 rats used for PET imaging on day 0, day 3, and
day 7 and molecular analysis on day 7. The second consisted of 14 rats
for the correlative experiment to access molecular analysis on day 3.
Moreover, one rat was sacrificed on day 0 as a baseline reference and
the others on day 3. Both cohorts consisted of five groups: untreated
control, control (excipients), BEZ-235, paclitaxel, and paclitaxel
plus BEZ-235.
In a second experiment aiming at further exploring the kinetics of
18F-FDG tumor uptake following drug cessation, we used a single
cohort of 10 animals consisting of untreated controls and rats receiv-
ing BEZ-235. In that cohort, animals were used for both PET
imaging and molecular analysis. For that purpose, one rat was sacri-
ficed on day 0 as a baseline reference, one animal was sacrificed on
day 3 and day 4 in both groups, and all remaining animals were
sacrificed after the last PET examination had been performed.
SA-PET/CT Acquisitions and Reconstruction Settings
Animals were kept fasting for 6 hours and were injected intra-
venously through the tail vein with a 29-gauge needle. Animals
received an average activity of 38 ± 7 MBq (first experiment) or
39 ± 5 MBq (second experiment) and were imaged 91 ± 8 minutes
(first experiment) or 105 ± 14 minutes (second experiment) follow-
ing injection.
SA-PET/CT examinations were performed on an Inveon SA-PET/
CT (Siemens Medical Solutions, Knoxville, TN). First, SA-CT images
were acquired over approximately 10minutes using 80 keV and 500 μA.
PET acquisitions were then performed using energy and coincidence
timing windows of 350 to 650 keV and 3.4 ns, respectively. Emission
scan duration was 10 minutes.
Reconstructions were performed using three-dimensional maximum
a posteriori (MAP) reconstruction with a 128 × 128 transaxial image
matrix size. Data were corrected for attenuation and scatter events.
OSEM-3D/MAP was employed with two OSEM-3D iterations and
18 MAP iterations with the smoothing parameter β set to 0.2.
SA-PET/CT Analysis
Data analysis was performed on a Siemens workstation dedicated to
SA-PET/CT interpretation. SA-PET and SA-CT images were inter-
preted by a researcher who was unaware of the treatments received by
the animals.
Three-dimensional regions or volumes of interest (VOIs) were
drawn over subcutaneous tumors by means of an isocontour set to
50%. The mean voxel values were extracted from each VOI, and
mean standardized uptake values (SUVs) were computed as follows:
SUV =
tumor activityðBq =mlÞ × body weightðgÞ
injected doseðBqÞ :
This kind of VOI is warranted when one wants to take into account
tumor heterogeneity. Residual activity of the syringe immediately
after injection and activity in the tail in the case that extravasation
occurred during tracer injection were subtracted from the activity
of the syringe. Activity in the tail was obtained by a VOI encompass-
ing the entire hot spot and corrected for decay to evaluate the activity
at the time of injection, assuming that no tracer absorption occurred
in the tail during the tracer uptake period.
Tumor volume was evaluated on CT slices according to the fol-
lowing formula:
Volume mm3
 
=
π × aðmmÞ × bðmmÞ × cðmmÞ
6
;
where a, b, and c are the long axis on coronal images and two per-
pendicular small axes at the level where the tumor appeared the
largest on transaxial images, respectively.
Western Blot
Cells were rinsed with ice-cold phosphate-buffered saline and
lysed in a lysis buffer [50 mM Tris-HCl (pH 8.1), 150 mM NaCl,
1%NP-40, 5mMEDTA, 10mMNaF, 4mMPMSF, 2mMaprotinin,
10 mM NaPPi, 1 mM Na3VO4, and a complete mixture of protease
inhibitors (Roche Applied Science, Meylan, France)] and incubated
on ice for 30 minutes. Lysates were then collected. After centri-
fugation (13,200g, 10 minutes, 4°C), protein concentrations were
determined using the Bradford assay (Bio-Rad, Hercules, CA). An
equivalent total amount of proteins was separated on sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (4-15%; Bio-Rad),
transferred onto a polyvinylidene fluoride membrane and blocked in
5% BSA. The primary antibodies were incubated overnight at 4°C:
phospho-AKT (1:1000), AKT (1:750), phospho-eukaryotic translation
initiation factor 4E–binding protein 1 (p4E-BP1; 1:500), 4E-BP1
(1:750) from Cell Signaling Technology (Danvers, MA), actin
(Millipore, Billerica, MA; 1:10,000), and tubulin (Sigma; 1:4000).
After washing, the membrane was incubated with secondary antibodies
conjugated with HRP [anti-rabbit at 1:10000 (Cell Signaling
Table 1. Experimental Design: Number of Animals and Tumor Samples Used for the SA-PET
Imaging and Correlative Experiments.
Experiment Cohort Day 0 Day 3 Day 4 Day 5 Day 7
Experiment 1 SA-PET/CT Control (untreated) 2 (8) 2 (8) – – 2 (8)
Control (excipients) 3 (12) 3 (12) – – 3 (12)
Paclitaxel 3 (12) 3 (12) – – 3 (12)
BEZ-235 3 (12) 3 (12) – – 1 (4)*
BEZ-235 + paclitaxel 3 (12) 3 (12) – – 2 (8)†
Correlative studies Control (untreated) 3 (12) 3 (12) – – ‡
Control (excipients) 3 (12) 3 (12) – – ‡
Paclitaxel 3 (12) 3 (12) – – ‡
BEZ-235 3 (12) 3 (12) – – ‡
BEZ-235 + paclitaxel 3 (12) 3 (12) – – ‡
Experiment 2 SA-PET/CT Control (untreated) 4 (16) 3 (12) 2 (8) 1 (4) –
BEZ-235 6 (24) 6 (24) 5 (20) 4 (16) –
Correlative studies Control (untreated) 1 (4) 1 (4) 1 (4) 1 (4) –
BEZ-235 1 (4) 1 (4) 4 (16) –
*Two animals had to be sacrificed because of significant weight loss.
†One animal had to be sacrificed because of significant weight loss.
‡Animals were sacrificed immediately after the SA-PET/CT had been performed and tumors used
for correlative studies on day 7.
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Technology) and anti-mouse at 1:5000 (Amersham,Waukesha, WI)]
for 1 hour at room temperature. The bands were visualized with the
ECL Prime (Amersham) and the SuperSignal West Femto Chemi-
luminescent Substrate (Pierce, Rockford, IL).
Immunohistochemistry Studies
Automated immunohistochemistry using a DakoCytomation
Autostainer was performed on 4-μm-thick paraffin sections. The
polyclonal antibody anti–Ki-67 was obtained from Novocastra
(A. Menarini Diagnostics, Antony, France); the polyclonal antibody
cleaved caspase-3 (Asp175) and the monoclonal p4E-BP1 (Thr37/46)
were obtained from Cell Signaling Technology (Ozyme, Saint Quentin
Yvelines, France).
Briefly, deparaffinized slides were treated for 30 minutes by the
high-temperature heating antigen retrieval technique in 0.01 M citrate
buffer (pH 6) for Ki-67 antibody or in CC1 buffer (pH 8; Ventana,
RocheDiagnostics,Meylan, France) for cleaved caspase-3 and p4E-BP1
antibodies to unmask epitopes. Sections were incubated with Ki-67
antibody (1:500), cleaved caspase-3 antibody (1:200), or p4E-BP1 anti-
body (1:50) for 1 hour at room temperature. After washing, slides were
incubated with Rabbit IgG Vectastain ABC Kit (Vector Laboratories,
Clinisciences, Nanterre, France) according to the manufacturer’s
instructions. Staining was revealed with DAB chromogen (Vector
Laboratories), and sections were counterstained with Hematoxylin QS
(Vector Laboratories).
The percentage of stained cells on the whole tumor sections was
estimated by an experienced pathologist, who was unaware of the
treatment groups.
Statistical Analysis
Data are presented as means ± SD. The change in SUVmean over
the different time points is reported as a percentage of baseline,
according to the following formula:
Change in SUV =
SUV on day x − SUV on baseline
SUV on baseline
× 100:
Statistical analysis was performed on a per-lesion basis.
In the first experiment, the nonparametric Kruskal-Wallis test was
used to compare percentage change in tumor uptake and tumor
volume in the control (untreated and excipients) and treated groups
(BEZ-235, paclitaxel, and BEZ-235 plus paclitaxel) at specific time
points. A post hoc test was performed with the Dunn test for
multiple comparisons.
In the second experiment, the nonparametric Mann-Whitney test
was used to compare percentage change in tumor uptake and tumor
volume in the untreated control and BEZ-235 groups at specific
time points.
For all tests, a two-tailed P value of .05 or less was considered
statistically significant. Statistical analysis, graphs, and plots were
performed with Prism (GraphPad Software, La Jolla, CA).
Results
Impact of Treatments on Tumor Growth
On baseline, tumor volume was lower in the paclitaxel group
compared to the BEZ-235 and the paclitaxel plus BEZ-235 groups.
On day 3 and day 7, there was no significant difference in tumor
volume, as assessed by CT among the BEZ-235 and the paclitaxel
plus BEZ-235 groups and the untreated control group (Figure 1).
18F-FDG Uptake after Treatment by BEZ-235, Paclitaxel,
and Paclitaxel Plus BEZ-235
18F-FDG uptake in tumors of animals that did not receive any
treatment (untreated control) continuously increased over time (+37%
on day 3 and +59% on day 7; Figure 3).
Figure 1. Impact of BEZ-235 on tumor growth. Mean ± SD value in
each group is shown.
Figure 2. 18F-FDG SA-PET response to BEZ-235 and paclitaxel plus
BEZ-235 compared to control groups. (A) Percentage variation
(mean ± SD) in SUVmean compared to baseline is shown on day 3
and day 7. The differences among different groups were tested
with the Kruskal-Wallis test, and post hoc test was performed with
the Dunn test for multiple comparisons; *, **, and *** indicate
two-tailed P < .05, P < .01, and P < .001, respectively. (B) Repre-
sentative transverse slices at the level of the subcutaneous pelvic
or thoracic tumors are shown for the different treatment and
control groups.
Translational Oncology Vol. 6, No. 5, 2013 18F-FDG and PI3K/mTOR Inhibition Lheureux et al. 589
Treatment with either paclitaxel or its excipient induced a small
decrease (−19%) in 18F-FDG tumor uptake on day 3 followed by
a return to baseline values on day 7. No difference in percentage
change between the control (excipients) and the paclitaxel groups
was observed on day 3 or on day 7.
Treatment with BEZ-235 given alone or after paclitaxel induced a
marked decrease in 18F-FDG uptake with a percentage decrease of
68% and 73%, respectively. Noticeably, this marked decrease was
homogeneous, as demonstrated by the narrow confidence intervals ob-
served (Figure 2) that can be compared to the larger confidence inter-
vals observed in the other treatment or control groups. This finding is
also visible when analyzing data on a per-animal basis (Figure W1).
Four days after treatment cessation, a partial tumor recovery occurred,
with percentage change of −31% and −26% compared to baseline in
the BEZ-235 and paclitaxel plus BEZ-235 groups, respectively. The
larger confidence interval observed in the paclitaxel plus BEZ-235
group is related to three of eight tumors (38%) that achieved an almost
complete recovery. Visually, treatment by BEZ-235 induced mostly a
marked and homogeneous decrease in 18F-FDG uptake, but a dramatic
decrease was also seen at the center of some tumors that was associated
with a persistent rim of significant uptake at the tumor edge. In the latter
case, the metabolic recovery observed at day 7 clearly began from the
edge of the tumor toward its center, as shown in Figure 2B.
Effect of BEZ-235 on the PI3K/mTOR Pathways
As shown by Western blot analysis (Figure 3B), BEZ-235 down-
regulated the key protein pAKT, a downstream marker of PI3K
activation. BEZ-235 also effectively decreased phosphorylation of
4E-BP1, a downstream marker of mTOR activation, as shown by
immunohistochemistry studies that revealed a marked and homo-
geneous decrease in the phosphorylation of 4E-BP1 on day 3 on the
whole tumor sections (Figure 3A).
On day 7, an almost complete recovery of PI3K/mTOR down-
stream occurred.
Effect of BEZ-235 on Cell Proliferation and Cell Death
On day 3, treatment with BEZ-235 given alone or after paclitaxel in-
duced a marked decrease in cell proliferation, as assessed by Ki-67
immunostaining, when compared to untreated controls (10% and 8%
vs 34%, respectively; P < .01). Compared to all other groups (Figure 4),
this decrease in cell proliferation in the BEZ-235 and paclitaxel plus
BEZ-235 groups was statistically significant. On day 7, no difference
in Ki-67 staining was observed between the control and treated groups
and Ki-67 staining almost returned to baseline values.
To fully characterize cell death, necrosis was studied at pathology
and apoptosis by immunohistochemistry (IHC) detection of cleaved
caspase-3, an early marker of the caspase cascade. There was no
necrosis or apoptosis detected in the treated groups compared to
control groups (Figure 5).
Further Analysis on 18F-FDG, PI3K/mTOR Pathways, and
Cell Proliferation Kinetics following BEZ-235 Withdrawal
18F-FDG uptake in tumors of animals that did not receive any
treatment (untreated control) remained higher than baseline values
Figure 3. BEZ-235 inhibits the PI3K/mTOR pathways. (A) Immunohistochemistry studies of representative tumors. The phosphorylation
of 4E-BP1 is markedly reduced on day 3 for the BEZ-235 conditions within all the tumor sections. Staining is similar to the control groups
on day 7. (B) Western blot of representative tumors: The administration of BEZ-235 inhibits the phosphorylation of AKT and 4E-BP1 on
day 3, and this effect is no longer observed on day 7.
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Figure 4. BEZ-235 inhibits tumor proliferation. (A) Quantification of Ki-67 staining (percentage of positive cells). The differences among
different groups were tested with the Kruskal-Wallis test, and post hoc test was performed with the Dunn test for multiple comparisons;
*, **, and *** indicate two-tailed P < .05, P < .01, and P < .001, respectively. (B) Immunohistochemistry studies of representative
tumors. Cell proliferation, as assessed by Ki-67 immunostaining, is markedly reduced on day 3 in the BEZ-235 and paclitaxel plus
BEZ-235 groups but is similar to control groups on day 7.
Figure 5. No evidence of cell death (apoptosis, necrosis) is observed after 3 days of treatment with BEZ-235. Immunohistochemistry and
hematoxylin eosin safran (HES) studies of representative tumors are shown. No necrosis or cleaved caspase-3 is observed in any of the
treatment conditions.
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(+40% on day 3, +19% on day 4, and +19% on day 5). Treatment
with BEZ-235 induced a marked decrease in 18F-FDG uptake with a
percentage decrease of −50% on day 3. Similarly to the first experi-
ment, this decrease was homogeneous, as demonstrated by the
narrow confidence intervals observed that can be seen when analyz-
ing data on a per-lesion (Figure 6) or on a per-animal basis
(Figure W1). The decrease in 18F-FDG tumor uptake persisted on
day 4 (−51%) and day 5 (−46%), and the difference in percentage
Figure 6. Further analysis on 18F-FDG, PI3K/mTOR pathways, and cell proliferation kinetics following BEZ-235 withdrawal. (A) Percent-
age variation (mean ± SD) in SUVmean compared to baseline is shown on day 3, day 4, and day 5. The differences among different
groups were tested with the Mann-Whitney test. (B) Immunohistochemistry studies of representative tumors. Cell proliferation, as
assessed by Ki-67 immunostaining, is markedly reduced from day 3 to day 5 in the BEZ-235 group compared to the control group.
In contrast, p4E-BP1 is markedly decreased on day 3 in the BEZ-235 group compared to the control group, but staining is almost similar
to the control groups on days 4 and 5. (C) Quantification of Ki-67 staining (percentage of positive cells). The differences among different
groups were tested with the Mann-Whitney test. (D) Western blot of representative tumors: The administration of BEZ-235 inhibits the
phosphorylation of AKT and 4E-BP1 on day 3. pAKT increased in a time-dependent manner on days 4 and 5, in contrast with p4E-BP1,
whose phosphorylation is more clearly visible on day 5.
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change in 18F-FDG in the BEZ-235 and untreated control groups
was statistically significant at all time points.
In contrast with 18F-FDG PET results, the PI3K/mTOR path-
ways exhibited partial recovery on day 4 and on day 5, as demonstrated
by IHC andWestern blot studies demonstrating a trend toward a nor-
malization of the phosphorylation of AKT and 4E-BP1. pAKT in-
creased in a time-dependent manner on days 4 and 5, in contrast
with p4E-BP1, whose phosphorylation was more clearly visible
on day 5.
From day 3 to day 5, cell proliferation assessment was congruent
with 18F-FDG PET imaging, with a Ki-67 staining significantly lower
in the BEZ-235 group than in the untreated control group.
Discussion
As most patients with ovarian cancer relapse within the first few years
following platinum-based chemotherapy because of chemotherapy
resistance [17], new targeted therapies are urgently needed [18].
Targeting the PI3K/mTOR pathway is a potential means of over-
coming chemoresistance in ovarian cancer. The present study shows
that 18F-FDG SA-PET is a surrogate marker of the early response to
a dual PI3K/mTOR inhibitor in a preclinical model of cisplatin-
resistant ovarian cancer, but that its ability to reflect pathway inhibi-
tion and cell proliferation depends on the delay between treatment
cessation and PET imaging. The effects of BEZ-235 on 18F-FDG
uptake by tumors were validated by a full range of molecular biology
techniques that on day 3 showed the extinction of key proteins
implicated in the PI3K/mTOR pathways. These findings were asso-
ciated with a significant decrease in cell proliferation, but no tumor
necrosis or apoptosis was depicted. Cell proliferation and PI3K/
mTOR downstream showed complete or almost complete recovery
4 days after treatment cessation, a pattern that was accurately iden-
tified by 18F-FDG SA-PET imaging at a time when no significant
change in tumor volume was depicted by SA-CT between the treated
and the control animals. At earlier time points after treatment cessa-
tion (i.e., 24 and 48 hours following BEZ-235 withdrawal), a lag
between PI3K/mTOR pathway recovery and 18F-FDG uptake that
remained unchanged was observed, whereas 18F-FDG was well cor-
related to cell proliferation.
The decrease in tumor 18F-FDG uptake during treatment with
AKT inhibition has been previously described by Ma et al. when
using rapamycin, an mTOR inhibitor [19], as a consequence of
temporarily decreased glycolysis mediated by a disruption of GLUT1
transporter transcription and/or translocation to the plasma
membrane, without effect on tumor growth. A translocation of
GLUT1 transporters was also reported by Nguyen et al. [20] after
3.5 hours of treatment with LY294002, an AKT inhibitor, in
human colon carcinoma cells xenografted into nude mice. In contrast
with the study from Ma et al. [19], our results show that the decrease
in 18F-FDG uptake correlates not only to target inhibition but
also to a significant decrease in cell proliferation within 3 days
of treatment.
Cejka et al. [16] have shown that 18F-FDG uptake can be used as
a surrogate marker for defining the optimal biologic dose of an
mTOR inhibitor, and several other preclinical studies have validated
the use of 18F-FDG PET as a marker of response to mTOR or AKT
pathway inhibition in various types of human cancers xenografted in
immunodeficient mice [15,16,21]. In none of these studies was
tumor recovery following drug withdrawal investigated. Therefore,
to the best of our knowledge, this study is the first to demonstrate
that 18F-FDG PET may predict cessation of pathway inhibition
early after drug withdrawal, although a lag between PI3K/mTOR
pathway recovery and metabolic recovery was observed during the
first 48 hours after drug withdrawal. Indeed, some tumors exhibited
a partial recovery of AKT as early as 24 hours after BEZ-235 drug
withdrawal, at a time when both cell proliferation and glucose
metabolism were still decreased. pAKT recovery was reached earlier
than p4E-BP1 phosphorylation, suggesting a preferential inhibition
of mTOR complex 1 (mTORC1) by BEZ-235, compared to
mTORC2. Indeed, it has been shown that mTORC1 could exert
an inhibitory effect on mTORC2 (through phospho-p70S6K)
[22,23], which is able to activate AKT (Ser473 phosphorylation). It
could be hypothesized that the maintained inhibition of mTORC1
after BEZ-235 withdrawal, but not of mTORC2, could lead to an
mTORC2-mediated AKT phosphorylation, whereas the targets of
mTORC1 such as 4E-BP1 remain unphosphorylated.
In our study, treatment with paclitaxel plus BEZ-235 was not
superior to BEZ-235 alone. This is in contrast with previous studies
showing an increased efficacy of paclitaxel plus a PI3K inhibitor on
tumor cell growth and dissemination as compared with either agent
alone [13]. In the present study, paclitaxel was given only once, on
the basis of what is done in the clinical setting [24]. Repeated admin-
istrations could have enhanced the antitumor activity of paclitaxel
[25–27]. It is noteworthy that, in our study, different metabolic
responses were observed in the paclitaxel and untreated control groups,
although no significant difference was noted between the excipients
and paclitaxel groups. These results could be related to the action of
the excipients by themselves. Indeed, several studies have shown that
Cremophor EL, the diluent in which paclitaxel is prepared for clinical
use, is a biologically active solvent [28–30].
Finally, our results raise questions when using 18F-FDG PET for
treatment assessment of molecular therapies that either have a short
life or target pathway(s) exhibiting recovery early after drug cessation.
Indeed, the delay between the last drug intake could lead to inaccu-
rate results if a patient was scanned several days after treatment
cessation, at a time when target inhibition is no longer present. This
delay could be determined not only by the prescription of the refer-
ring oncologist but also by non-adherence to treatment. Adherence,
which is the extent to which a person’s behavior taking medication
corresponds with agreed recommendations from the healthcare pro-
vider, is a major and sometimes unrecognized source of variability in
the clinical setting [31]. However, adherence has been poorly explored
in solid tumors, mainly in the setting of chronic administration
[32,33], despite the increased prescription of oral target therapies.
To the best of our knowledge, a precise recording of the last drug
intake before PET scanning (i.e., the date and if possible, precise hour)
is neither routinely done in PET units nor recommended by the
European Association of Nuclear Medicine (EANM) [34] or Society
of Nuclear Medicine (SNM) [35] guidelines for tumor imaging. This
information is unlikely to be obtainable a posteriori, and we feel that
it should be recorded in a systematic way, so that its impact on PET
results can be assessed. Information regarding this issue can be drawn
from a recent study that attempted to determine compliance with
PET protocol parameters defined in the imaging charter within a
multicenter trial in patients with non-small cell lung cancer (NSCLC)
treated with erlotinib [36]. This study demonstrated that more than
90% of patients completed the scheduled PET scans within the ex-
pected window (that is 14 and 56 days following treatment initiation)
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± 3 days. This suggests that good levels of compliance are achievable if
one decides to systematically incorporate information regarding the
time passed since the last drug intake into the PET reports.
Conclusion
18F-FDG SA-PET is a surrogate marker of target inhibition during
treatment with BEZ-235 and predicts tumor recovery 4 days after
drug withdrawal, but not during the first 48 hours following drug
cessation, when a lag between PI3K/mTOR pathway recovery and
metabolic recovery is observed. The results of this study suggest that
18F-FDG PET could be used for therapy monitoring of PI3K/mTOR
inhibitors in cisplatin-resistant ovarian cancer. However, they also
raise questions regarding the potential impact of the delay between
PET imaging and last drug intake on the accuracy of 18F-FDG PET
imaging when evaluating such inhibitors or other molecular therapies
that target pathway(s) exhibiting recovery early after drug cessation.
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Figure W1. Percentage variation in SUVmean compared to baseline
is shown for each experiment. Each bar denotes mean ± SD for a
given animal. The differences among different groups were tested
with the Kruskal-Wallis test, and post hoc test was performed with
the Dunn test for multiple comparisons; * indicates a two-tailed
P < .05.
